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Abstract A gene expression score (GES) for obstructive
coronary artery disease (CAD) has been validated in two
multicenter studies. Receiver-operating characteristics
(ROC) analysis of the GES on an expanded Personalized Risk
Evaluation and Diagnosis in the Coronary Tree (PREDICT)
cohort (NCT no. 00500617) with CAD defined by quantita-
tive coronary angiography (QCA) or clinical reads yielded
similar performance (area under the curve (AUC)=0.70, N=
1,502) to the original validation cohort (AUC=0.70, N=526).
Analysis of 138 non-Caucasian and 1,364 Caucasian patients
showed very similar performance (AUCs=0.72 vs. 0.70). To
assess analytic stability, stored samples of the original valida-
tion cohort (N=526) was re-tested after 5 years, and the mean
score changed from 20.3 to 19.8 after 5 years (N=501, 95 %).
To assess patient scores over time, GES was determined on
samples from 173 Coronary Obstruction Detection by Molec-
ular Personalized Gene Expression (COMPASS) study (NCT
no. 01117506) patients at approximately 1 year post-enroll-
ment. Mean scores increased slightly from 15.9 to 17.3, cor-
responding to a 2.5 % increase in obstructive CAD likelihood.
Changes in cardiovascular medications did not show a signif-
icant change in GES.
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Introduction
The diagnosis of obstructive coronary artery disease (CAD)
specifically, and atherosclerosis, more broadly, is a significant
challenge. Although a variety of non-invasive testing are
usually performed in patients with symptoms suggestive of
CAD, including stress ECG, echocardiography, and myocar-
dial perfusion imaging, less than half of patients without
known CAD have significant disease upon invasive angiog-
raphy [1]. Especially as the prevalence of significant CAD has
decreased, improved risk stratification and more sensitive
methods for detecting obstructive CAD are needed, to reduce
the costs and morbidity associated with invasive testing [2].
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Clinical Relevance This work extends the evidence for a promising
technology, peripheral blood gene expression testing for symptoms
suggestive of obstructive coronary artery disease, by extending the
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measurement, both analytically and in serial measurements over a 1 year
time frame.
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Given the central role of a maladaptive inflammatory re-
sponse in atherosclerosis and CAD development [3, 4], we
analyzed peripheral blood gene expression in a series of
microarray and real-time PCR (RT-PCR) studies, as a possible
methodology for the sensitive, non-invasive, and non-
radiation-utilizing detection of CAD [5]. These observations
led to the development [6] of a gene expression score (GES)
for obstructive CAD likelihood, comprising 23 gene expres-
sion levels, age, and sex, which is reported on a 1–40 scale,
with subsequent validation in two multicenter studies [7, 8]
(Personalized Risk Evaluation and Diagnosis in the Coronary
Tree (PREDICT) and Coronary Obstruction Detection by
Molecular Personalized Gene Expression (COMPASS)), in
almost 1,000 non-diabetic patients referred for invasive angi-
ography and myocardial perfusion imaging, respectively. In
addition, the GES was shown to be significantly correlated
with a composite endpoint of cardiovascular events and re-
vascularizations [9].
Although the overall evidence for the utilization of gene
expression testing for CAD diagnosis is promising [10], addi-
tional questions such as the reproducibility of the technology
[11], dependence of test performance on ethnicity [12], and
the schedule of testing have been raised. In this work, we
describe testing of more than 1,500 patients from the PRE-
DICT study, including those of various ethnicities, and the
variation in the GES in serial testing over 1 year in 192
patients from the COMPASS study.
Methods
Study Populations For the PREDICT (NCT no. 00500617)
study, a total of 2,811 non-diabetic subjects were recruited. This
entire study encompassed the gene discovery, development,
and first validation study for the GES [6, 7], as well as post-
validation cohorts. PREDICTenrolled symptomatic patients or
high-risk asymptomatic subjects clinically referred for invasive
coronary angiography, with no previously known history of
CAD or revascularization. Key exclusion criteria included
acute coronary syndromes, severe non-coronary cardiovascular
disease, systemic infectious or inflammatory diseases, and the
use of immunosuppressant or chemotherapeutic agents. For the
current study, subjects enrolled after the completion of the
discovery and development phases (N=896) were included
(N=1,733). Post-validation recruitment was limited to non-
diabetics and preferentially enrolled female subjects.
The second section of this work is based on an extension of
the COMPASS (NCT no. 01117506) study population of 431
patients. The COMPASS study enrolled symptomatic non-
diabetic patients with no history of MI or revascularization
who were clinically referred for myocardial perfusion imaging
[8], with similar exclusion criteria as for PREDICT. Patients in
this study either had invasive angiograms, if clinically indicated,
or research CTangiograms to determine coronary anatomy. The
top four enrolling sites in this study were approached, IRB
approval obtained, and patients at these sites consented for a
second blood draw approximately 1 year after study entry.
Acquisition of Angiograms and Core Laboratory
Measurements For PREDICT, analyses were performed on
both the clinical invasive angiography reads, performed ac-
cording to site protocols, as well as the quantitative coronary
angiographic (QCA) reads, determined as described previous-
ly [7, 13]. Cases were defined as ≥70 % stenosis by clinical
read or ≥50 % stenosis by QCA based on prior work [7]. For
COMPASS, anatomical data at study entry were determined
by QCA if invasive angiograms were performed or by core-
laboratory CTangiography as described [14]. Core-laboratory
measurements by two independent readers were utilized to
define cases as ≥50 % stenosis [8].
Measurement of Gene Expression Score We utilized a previ-
ously validated quantitative RT-PCR (qRT-PCR)-based pe-
ripheral blood gene expression test run in a CLIA-certified
laboratory (Corus® CAD; CardioDx, Inc; Palo Alto, CA,
USA) [6, 7, 15], which is comprised of age, sex, and RNA
levels of 23 genes expressed in peripheral blood cells. The test
reports a score of 1–40, with higher scores associated with
higher likelihood of obstructive CAD. Whole blood samples
were collected in PAXgene® tubes (Pre-Analytix, Valencia,
CA, USA) prior to myocardial perfusion imaging (MPI) or
invasive angiography, treated according to the manufacturer’s
instructions, then frozen at −20 °C. RNA purification, cDNA
synthesis, and qRT-PCR were performed as previously de-
scribed with the median values for all PCR reactions used for
score calculation [6, 7, 15]. The GES was calculated from
patient age, sex, and the median Cp values for the 23 genes as
shown in the supplementary files [6, 7]. All GES measure-
ments were run in 2013 on stored samples and where appro-
priate compared to the original values obtained in 2008 and
reported previously [7].
Statistical Analysis Analyses were done in R Version 3.1.0
[16] and used the lm function for linear regression, the aov
function for ANOVA, and the rcorr.cens function in the Hmisc
library for receiver-operating characteristics (ROC) analysis.
Continuous variables were expressed as mean±SD or as me-
dian (inter-quartile range), as appropriate based on the distri-
bution. Continuous variables were compared by t test (two-
tailed) and categorical variables using the chi-squared test.
Results
The PREDICT study enrolled a total of 3,728 subjects of
whom 2,811 were non-diabetics, divided into sequential
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cohorts for gene discovery, algorithm development, valida-
tion, and post-validation studies, and stratified by the avail-
ability of clinical versus QCA angiographic data (Fig. 1). For
this work, a total of 1,502 patients were analyzed for whom
clinical and demographic data, invasive angiography, and
GES were obtained. In addition, subsets corresponding to
the original validation set (N=648), and those for whom
QCA had been performed (N=1,038), were analyzed. Clinical
and demographic data for these cohorts are detailed in Tables 1
(validation set) and 2 (complete QCA and clinical sets).
To determine sample and process stability, we measured
GES for the validation set (N=648) [7] from PAXgene® tubes
stored at −20 ° C for approximately 5 years. In the original
analysis, GES had been obtained for 526 subjects, whereas in
the current iteration, a total of 594 passed GES QC, with an
intersection of 501 subjects. Clinical and demographic data
for these groups did not differ significantly with 56 % male,
(average age 60 years), 90 % non-Hispanic Whites, 69 %
symptomatic and 31 % asymptomatic presentation, 37 %
obstructive CAD (≥50 % stenosis by QCA), and mean GES
of 19.8 (Table 1). The average change in the GES between the
original work performed in 2008 and the current testing per-
formed in 2013 for this group (N=501) was 0.53, on the 1–40
scale, corresponding to approximately a 1 % change in disease
likelihood. There was no significant change in test perfor-
mance by ROC analysis between the original and most recent
data sets (area under the curve (AUC)=0.70 for both, N=501)
(Table 3).
The complete QCA cohort (N=1,028) included subsequent
preferential enrollment of female subjects raising the percent-
age to 55 % overall but otherwise was similar with respect to
demographic parameters (average age 60 years, 91 % non-
Hispanic Whites, 71 % symptomatic, and 33 % obstructive
disease by QCA (28 % by clinical read of ≥70 % stenosis))
with a mean GES of 18.3. The complete clinical cohort (N=
1,502), which includes the QCA cohort, was 54 % female and
showed similar characteristics with 27 % obstructive disease
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Fig. 1 Patient flow for the PREDICT study cohorts. A total of 3,728
patients who met the original inclusion criteria were enrolled, comprising
2,811 non-diabetic and 911 diabetic subjects, with only the former as
candidates for the current studies. Those non-diabetic subjects involved in
previous discovery and development efforts (N=814) as well as 264 who
did not have invasive angiograms were excluded, yielding 1,733 subjects
with clinical angiographic reads. There were 177 laboratory exclusions,
resulting in 1,556 (90%)which yielded valid GESmeasurements. For the
QCA subset, a total of 1,082 patients were tested and the final set
comprised 1,028 patients (95 %, 54 did not pass GES QC). There were
an additional 474 subjects with clinical angiographic reads and GES
yielding the final clinical cohort of 1,502







N 648 526 594 501
Female 285 (44 %) 227 (43 %) 266 (45 %) 222 (44 %)
Age 60 60 60 60
Race—White-
non-Hispanic
580 (90 %) 474 (90 %) 540 (91 %) 453 (90 %)
Chest pain
Typical 263 (41 %) 213 (41 %) 246 (41 %) 207 (41 %)
Atypical 162 (25 %) 133 (25 %) 149 (25 %) 127 (25 %)
Non-cardiac 12 (2 %) 12 (2 %) 12 (2 %) 12 (2 %)
None 210 (33 %) 167 (32 %) 187 (32 %) 155 (31 %)
Hypertension 425 (66 %) 345 (66 %) 391 (66 %) 331 (66 %)
Dyslipidemia 426 (68 %) 341 (67 %) 395 (69 %) 324 (67 %)
BMI 30.8 30.7 30.7 30.8
Systolic BP 135.8 135.2 135.6 135.3
Diastolic BP 78.6 78.1 78.7 78.2
Smokinge 115 (18 %) 92 (18 %) 109 (18 %) 88 (18 %)
CAD by QCAf 238 (37 %) 192 (37 %) 219 (37 %) 184 (37 %)
CAD by clinical
readg
195 (30 %) 161 (31 %) 183 (31 %) 154 (31 %)
a The complete validation set described in Elashoff et al. [6] without one
patient who was a late clinical exclusion for diabetes
b Those patients whose samples passed all metrics for inclusion in the
original validation study completed in 2008
c Patients from the full set who passed all GES metrics for inclusion for
data completed in 2013
d The patients for whom GES was obtained in both 2008 and 2013
e Smoking refers to current smoking
f Patients were defined as cases with CAD using ≥50 % stenosis by QCA
g Patients were defined as cases with CAD using ≥70 % stenosis by
clinical read
J. of Cardiovasc. Trans. Res. (2014) 7:615–622 617
ROC analysis for all data sets showed very similar results
to the original validation study (Table 3) with no significant
difference by sex or clinical versus QCA case-control defini-
tions. Analysis of non-Hispanic Whites (N=1,364) and other
ethnicities (N=138) showed significant and similar AUCs for
both groups (Table 3).
The above results demonstrate sample and GES analytical
stability but not the extent of biological variation over time on
a per patient basis. To address this question, a subset of
patients from the COMPASS study, who had been referred
for myocardial perfusion imaging for suspected CAD, were
re-consented. A second blood sample was obtained approxi-
mately 1 year after the index blood samples, which formed the
basis of the previous results (Fig. 2). A pre-specified GES
threshold of 15 was derived from the PREDICT validation
results and validated in COMPASS with a sensitivity of 89 %
and negative predictive value of 96 % [8]. Demographics for
the complete COMPASS set of 431 patients for whom MPI,
invasive angiography or CTA, and GESwere obtained and the
195 patient subset for whom second blood samples were
obtained are shown in Table 4. The mean age was 57 years,
49 % female; GES was obtained on 192 (98 %). Of these, 19
patients were censored due to revascularizations [17] and
events [2] between index and 1-year sampling. For the
Table 2 Clinical and demographic characteristics of PREDICT valida-







N 594 1028 1502
Female 285 (44 %) 561 (55 %) 809 (54 %)
Age 59 60 60
Race (White–non-Hispanic) 540 (91 %) 936 (91 %) 1364 (91 %)
Chest Pain
Typical 246 (41 %) 438 (43 %) 651 (43 %)
Atypical 149 (25 %) 276 (27 %) 401 (27 %)
Non-cardiac 12 (2 %) 19 (2 %) 32 (2 %)
None 187 (32 %) 294 (29 %) 415 (28 %)
Hypertension 391 (66 %) 681 (67 %) 978 (66 %)
Dyslipidemia 395 (69 %) 671 (68 %) 975 (67 %)
BMI 30.7 30.4 30.3
Systolic BP 136 135 135
Diastolic BP 79 78 79
Smoking 109 (18 %) 186 (18 %) 277 (19 %)
CAD by QCA 219 (37 %) 343 (33 %) 343 (33 %)
CAD by clinical read 183 (31 %) 291 (28 %) 410 (27 %)
a The complete set of PREDICT patients for whom GES results were
obtained in the 2013 testing
b The entire number of patients for whom QCA and GES results were
obtained, including those in the new validation set
c All the non-diabetic patients in the study (see Fig. 1) who had clinical
invasive angiographic reads and GES, determined in 2013
Table 3 ROC analysis for obstructive CAD of all subject data setsa
Data set N AUC Std error p value
Original validation (2008)b 526 0.70 0.02 <0.001
Males—original validation 299 0.66 0.03 <0.001
Females—original validation 227 0.65 0.05 0.0015
New validation (2013)c 594 0.70 0.02 <0.001
Males—2013 validation 328 0.66 0.03 <0.001
Females—2013 validation 266 0.64 0.04 0.001
Common validation setd 501 0.70 0.02 <0.001
Total QCA population 1,038 0.70 0.02 <0.001
Clinical read on QCA population 1,038 0.68 0.02 <0.001
Clinical read entire population 1,502 0.70 0.02 <0.001
Males—clinical read—all 693 0.66 0.02 <0.001
Females—clinical read—all 809 0.64 0.03 <0.001
White—non-Hispanic—all 1,364 0.70 0.02 <0.001
Non-White—alle 138 0.72 0.06 0.0002
a For QCA, obstructive CAD was defined as ≥50 % stenosis; for clinical
reads, the threshold was ≥70 %
b Patients from theN=648 cohort for whomQCA andGESwere obtained
as reported in Rosenberg et al. [7]
c Patients from theN=648 cohort for whomQCA andGESwere obtained
in 2013
d The intersection of the 526 and 594
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Fig 2 Patient enrollment and flow for COMPASS (NCT 01117506)
study index and follow-up GES measurements. From the original 431
COMPASS subjects (all non-diabetic) with CT or invasive angiograms,
GES, and MPI, the four highest enrolling sites enrolled 295. A total of
195 (66 %) consented and were enrolled for the second-draw study with
GES being obtained on 192 (98 %); of these, 173 did not have events or
procedures prior to the second GES measurement
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remaining 173, the index GES was correlated with maximum
percent stenosis (Fig. 3a), as was seen in the entire cohort.
Between the index and second blood samples, mean scores
increased from 15.9 to 17.3, corresponding to a 2.5 % increase
in obstructive CAD likelihood by logistic regression, with
approximately half of the increase due to increased patient
age. The change in GES between patient samples was inde-
pendent of index GES (Fig. 3b) and maximum percent steno-
sis at study entry (Fig. 3c). For those patients with revascular-
izations or events, the average score change was 1.1, similar to
that for those without (Supplementary Table 1).
A total of 12 patients (7%) had scores that crossed the GES
threshold of 15 between index and 1-year samples, nine
increased and three decreased, none of whom had obstructive
CAD at baseline. Only four patients (2 %) had score changes
>10. The number of cardiovascular medications (for dyslip-
idemia and hypertension) prescribed during the study period
increased in 29 patients without a significant change in their
GES (change in score 0.7 vs. 1.5, p=0.25).
Discussion
There are four major conclusions from this study about the
analytical and clinical validity of this gene expression score
for obstructive CAD: (1) Expansion of the PREDICT valida-
tion cohort by almost 1,000 patients to over 1,500 subjects
with clinical angiographic reads yielded the same test perfor-
mance as in the original report. (2) In this significantly larger
clinical read population, subjects of non-White ethnicity
(N=138) showed significant and similar performance as
Whites (ROC AUC=0.72±0.06, p<0.001). (3) The RT-PCR
platform for the GES was analytically robust yielding the
same performance in 501 subjects from the original validation
study with little change in score over a 5-year period. (4) To
examine the biological variation in GES over time, a second
blood sample was obtained 1-year post-enrollment, from pa-
tients in the COMPASS study, and showed overall a small
change in GES and little effect due to changes in cardiovas-
cular medications.
The expanded results from the PREDICT study both repli-
cated prior data and added to them by examining clinical
angiographic reads as well as QCA. Other work has shown
that QCA is more conservative than clinical reads [17], and
our results show perhaps an even larger difference in stenosis
measurement between these methods in this larger cohort (N=
1,038). A further analysis of these results using multivariate
methods could prove interesting. Prior work on the analytical
performance of this GES showed that the overall 95 % confi-
dence intervals were approximately 2 units from the mean
[15]. In this work, we show that 78 % of patients fell within
this range with re-testing after 5 years of sample storage.
These results suggest that PAXgene tube blood RNA stability
is longer than what has been shown previously [18].
It has been suggested that given differences in both the
prevalence of CAD [12] and the relative proportions of calci-
fied plaque in different ethnicities [19] that further studies on
this GES were needed. The current work suggests that the
overall performance of the GES is similar in different ethnic-
ities, although further work in larger cohorts, enabling multi-
variate analyses in these populations, would be desirable.
With respect to plaque composition, since the GES is sensitive
Table 4 Clinical and demographic characteristics of COMPASS cohorts
Clinical variable Overall study N=431a Top sites N=295b Enrolled patients N=192c
% obstructive CAD—core labd 0.15 0.15 0.17
Male 225 (52 %) 159 (54 %) 95 (50 %)
Race—White 383 (89 %) 273 (93 %) 179 (93 %)
Age (years)e 56 +/− 10 55 +/− 10 57 +/− 10
Systolic BP (mmHg) 130 +/− 17 131 +/− 18 131 +/− 18
Dyslipidemia 236 (55 %) 163 (55 %) 112 (58 %)
BMI 30 +/− 6 30 +/− 6 30 +/− 6
Smoker
Current 66 (15.3 %) 45 (15.3 %) 24 (12.5 %)
Aspirin 212 (49 %) 150 (51 %) 104 (54 %)
Beta-blockers 86 (20 %) 66 (22 %) 42 (22 %)
ACE inhibitors 130 (30 %) 89 (30 %) 62 (32 %)
a The set of patients analyzed in Thomas et al. [8] for whom core-lab QCA or CTA, MPI, and GES were obtained
b The top four enrolling sites in the COMPASS study representing 68 % of subjects
c Patients from the top four sites who consented to the second blood draw and for whom a second GES was obtained (192/195=98 %)
dObstructive CAD was defined as ≥50 % stenosis by either QCA or core-lab CTA as described in Thomas et al. [8]
e Clinical or demographic factors which differed between obstructive CAD cases and controls are indicated in bold face
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to both calcium score and overall plaque burden [14], the
changes in the proportion of calcified plaque in different
ethnicities may not have a large influence on the score.
The results from the sequential draws in the COMPASS
study population show overall small changes over a 1-year
time frame. Given the demonstrated quantitative relationship
between the GES and atherosclerotic plaque burden, mea-
sured cross sectionally in both the PREDICT and COMPASS
studies [7, 8, 14], these results suggest that disease progression
is not a major factor over this time frame. Results from
sequential CT-angiographic studies also show relatively mod-
est disease progression over 1 to 2 years, although this may be
confounded by medication effects on plaque progression and
composition [20, 21]. Finally, there was little effect of medi-
cation changes on the GES, although the patient numbers
analyzed are relatively modest. Given that the GES was de-
rived from a mixed population with respect to medication use,
it is unlikely that highly medication-sensitive genes would
have been selected as CAD classifiers. A recent study exam-
ining intensive cardiovascular risk reduction in a post-MI
population with sequential microarray analyses also showed
little effect of medications on gene expression [22]. Specifi-
cally with respect to the GES, only one gene present in the
algorithm (S100A12) was shown to be significantly changed
in this risk reduction study [22].
These current studies of the GES have limitations. First,
they are restricted to patients without known CAD or previous
MI who are non-diabetic and do not have chronic inflamma-
tory diseases. Second, the PREDICT population is at higher
risk than the clinical population seen on suspicion of CAD in
primary care or cardiology. It is subject to referral bias, since
subjects were already referred for invasive angiography, and is
also biased towards females in the largest cohorts. However,
previously reported results in the COMPASS study suggest
that test performance is relatively insensitive to disease prev-
alence [8], and in current and previous work, GES perfor-
mance is similar for males and females [23]. Third, not all of
the PREDICT patients have QCA as an anatomical gold
standard, although GES performance appears to be consistent
between QCA and clinical reads, when the difference in
stenosis observed by the two methods is taken into account.
Fourth, the COMPASS second blood draw results lack paired
second anatomical measurements, which could have been
useful to inform upon the small number of patients with
significant score changes, and the PREDICT populations did
not have a second blood draw. Lastly, although the GES
provides a stable and reproducible measure of obstructive
CAD likelihood, with reasonable overall diagnostic accuracy
[14], the additional classification power which might be pro-
vided by other existing biomarkers or additional genomic
modalities, such as epigenetics, common genetic polymor-
phisms, circulating micro-RNAs, and others, was not investi-
gated and is unknown. In addition, gene discovery by next-
generation RNA sequencing may identify additional classi-
fiers as has been shown in breast cancer [24].
In summary, we have expanded the original PREDICT
GES validation cohort to more than 1,500 patients and dem-
onstrated very similar and significant performance in White
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Fig 3 COMPASS analyses of index and second-draw GES. a Relation-
ship between index GES and maximum percent stenosis determined by
core-laboratory CTA or QCA for the 173 patients without events or
procedures between GES measurements is shown. Core-laboratory max-
imumpercent stenosis (MPS) was determined as described [8], in stenosis
categories by two independent readers. The median of the category
stenosis range is used in each case. The GES is significantly correlated
with MPS (r=0.39, p<0.001). b Relationship of the change in GES over
1 year to the index GES value is shown. For the same 173 patients, the
average GES between index and second-draw measurements increased
from 15.9 to 17.3, but there was no dependence of this change on the
index GES value (r<0.01, p=NS). c Relationship of the change in GES
between index and second GES measurements on index maximum per-
cent stenosis is shown. There was no significant dependence of the
change in GES on index stenosis (r<0.01, p=NS)
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stability over a 5-year period also demonstrated on the original
validation samples. The biological variation of the GES over
time was tested by examining second-draw samples from a
subset of COMPASS study patients approximately 1-year
post-study enrollment with little or no change in GES over
this time period in the vast majority of patients and no signif-
icant effect of changes in cardiovascular medications.
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